MARKET

SILK

SILK

Silk Road Medical
NASDAQ
54.95
+1.13
+2.10%
After Hours: 55.00 +0.05 +0.09% 17:49 01/27 EST
OPEN
53.55
PREV CLOSE
53.82
HIGH
55.15
LOW
53.32
VOLUME
269.91K
TURNOVER
0
52 WEEK HIGH
58.04
52 WEEK LOW
27.21
MARKET CAP
2.09B
P/E (TTM)
-33.7676
1D
5D
1M
3M
1Y
5Y
Healthcare Outlook 2023
Seeking Alpha · 5d ago
Insider Sell: Silk Road Medical
Insider Sell: Silk Road Medical
MT Newswires · 01/20 01:35
Argus Research Adjusts Silk Road Medical's Price Target to $70 From $60, Maintains Buy Rating
Argus Research Adjusts Silk Road Medical's Price Target to $70 From $60, Maintains Buy Rating
MT Newswires · 01/09 13:37
Silk Road Medical (SILK) is a Great Momentum Stock: Should You Buy?
Does Silk Road Medical (SILK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks · 12/05/2022 17:00
Silk Road Medical (SILK) Reports Q3 Loss, Tops Revenue Estimates
Silk Road Medical (SILK) delivered earnings and revenue surprises of 34.09% and 10.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/09/2022 00:35
BRIEF-Silk Road Medical Reports Third Quarter 2022 Financial Results
Reuters · 11/08/2022 23:07
Silk Road Medical GAAP EPS of -$0.29 beats by $0.14, revenue of $37.4M beats by $3.76M
Seekingalpha · 11/08/2022 21:56
Silk Road Medical Q3 EPS $(0.29) Beats $(0.42) Estimate, Sales $37.37M Beat $33.50M Estimate
Benzinga · 11/08/2022 21:12
More
About SILK
Silk Road Medical, Inc. is a medical device company, which is focused on reducing the risk of stroke and its devastating impact. The Company has discovered an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR), which relies on two concepts: minimally invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain and combines the benefits of innovative endovascular techniques with fundamental surgical principles. The Company's ENROUTE Transcarotid Neuroprotection System (NPS) and ENROUTE Transcarotid Stent System are the products for use in TCAR. Its ENROUTE Transcarotid Stent System is placed during a period of temporary high-rate blood flow reversal, which is enabled by its ENROUTE Transcarotid NPS. It markets and sells its products in the United States through a direct sales organization consisting of approximately 64 sales representatives and 62 clinical support specialists.

Webull offers kinds of Silk Road Medical Inc stock information, including NASDAQ:SILK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SILK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SILK stock methods without spending real money on the virtual paper trading platform.